

**CLASS:** A

**PROTOCOL(S) USED IN:** Pain Management, Abdominal Pain, IM Access and Infusion

**PHARMACOLOGY AND ACTIONS:**

- A. Analgesic
- B. Peripheral vasodilator
- C. Pupil constriction
- D. Respiratory depressant
- E. Cardiac effect of vasodilation decreases myocardial oxygen consumption, decreases left ventricular end-diastolic pressure, decreases cardiac workload, may decrease incidence of dysrhythmias.

**INDICATIONS:**

- A. Pain control
- B. Pulmonary edema
- C. Back and neck injuries when sedation/pain relief are necessary to prevent a patient from moving around and potentially injuring themselves.

**CONTRAINDICATIONS:**

- A. Systolic B/P < 90 mmHg
- B. Patients with respiratory difficulties except for pulmonary edema.
- C. Moderate to severe respiratory depression.
- D. Decreased level of consciousness.

**SIDE EFFECTS AND NOTES:**

- A. Respiratory depression
- B. Decreased BP
- C. Decreased level of consciousness
- D. Decreased heart rate
- E. N/V
- F. Have Naloxone available to reverse over administration
- G. Allergic reactions - Sulfa drugs are not sulfates
- H. May follow administration with Ondansetron for nausea

**ADULT DOSING:**

**Pain Management**

2 - 10 mg IV/IM/IO. Repeat q 3 - 5 min to max of 20 mg.

**PEDIATRIC DOSING:**

**Pain Management (< 20kg)**

0.1 mg / kg IV/IM/IO. May repeat q 3-5 min. Do not exceed adult dosing.